Aptorum Group Ltd Cl A (APM)

2026-03-10T12:26:35.000Z - 3 months ago

Aptorum Group, DiamiR announce publication of microRNA biomarker study

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

2026-03-06T21:35:49.000Z - 3 months ago

Aptorum Group receives noncompliance notification from Nasdaq

2026-02-02T13:16:57.000Z - 4 months ago

Aptorum Group announces collab between DiamiR, Instant NanoBiosensors

Feb 2, 2026, 8:00 AM EST - 4 months ago

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

2026-01-16T21:35:30.000Z - 4 months ago

Aptorum Group files $75M mixed securities shelf

Nov 19, 2025, 8:00 AM EST - 7 months ago

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

2025-11-17T21:35:21.000Z - 7 months ago

Aptorum Group files to sell 2.06M Class A ordinary shares for holders

2025-10-10T14:01:00.000Z - 8 months ago

Aptorum Group announces up to $6M registered direct offering

Oct 10, 2025, 9:54 AM EDT - 8 months ago

Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

2025-10-09T13:00:28.000Z - 8 months ago

Aptorum Group appoints Laura Philips to board of directors

Oct 9, 2025, 8:55 AM EDT - 8 months ago

As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

Sep 5, 2025, 8:00 AM EDT - 9 months ago

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-22T01:37:00.000Z - 10 months ago

Why Is Aptorum Stock (APM) Up 115% Today?

2025-08-21T11:15:32.000Z - 10 months ago

Aptorum Group, DiamiR announce New York state approval for APOE Genotyping test

Aug 21, 2025, 7:07 AM EDT - 10 months ago

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

2025-08-04T12:20:52.000Z - 10 months ago

Aptorum Group regains compliance with Nasdaq minimum bid price rule

Aug 4, 2025, 8:15 AM EDT - 10 months ago

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

2025-07-16T13:10:10.000Z - 11 months ago

Aptorum Group Ltd trading resumes

2025-07-16T12:46:22.000Z - 11 months ago

Aptorum Group, DiamiR Biosciences entered definitive merger agreement

Jul 16, 2025, 8:38 AM EDT - 11 months ago

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

2025-07-16T12:16:29.000Z - 11 months ago

Aptorum Group Ltd trading halted, news pending

2025-04-16T16:35:18.000Z - 1 year ago

Aptorum Group receives Nasdaq non-compliance notification

Apr 16, 2025, 12:27 PM EDT - 1 year ago

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 8, 2025, 11:30 AM EST - 1 year ago

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

2025-01-02T16:00:12.000Z - 1 year ago

Aptorum Group announces pricing of $3M registered direct offering

Jan 2, 2025, 10:55 AM EST - 1 year ago

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Dec 20, 2024, 4:00 PM EST - 1 year ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Apr 30, 2024, 9:15 AM EDT - 2 years ago

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

2024-03-19T14:36:06.000Z - 2 years ago

Aptorum Group Ltd trading resumes

2024-03-19T14:31:06.000Z - 2 years ago

Aptorum Group Ltd trading halted, volatility trading pause

Mar 6, 2024, 8:00 AM EST - 2 years ago

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Dec 22, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Dec 21, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Nov 16, 2023, 11:00 AM EST - 2 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aug 10, 2023, 2:57 AM EDT - 3 years ago

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Jun 22, 2023, 8:00 AM EDT - 3 years ago

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Jun 9, 2023, 4:30 PM EDT - 3 years ago

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

May 5, 2023, 4:31 PM EDT - 3 years ago

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

May 1, 2023, 8:00 AM EDT - 3 years ago

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Apr 28, 2023, 9:44 AM EDT - 3 years ago

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Mar 17, 2023, 8:15 AM EDT - 3 years ago

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ASPI

Mar 3, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Mar 3, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Mar 2, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Feb 10, 2023, 4:30 PM EST - 3 years ago

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Feb 6, 2023, 10:08 AM EST - 3 years ago

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Jan 20, 2023, 8:22 AM EST - 3 years ago

Aptorum Group Announces 1-for-10 Reverse Stock Split

Jan 4, 2023, 9:00 AM EST - 3 years ago

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Dec 22, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Dec 16, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Dec 9, 2022, 7:00 AM EST - 3 years ago

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Nov 25, 2022, 8:30 AM EST - 3 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Nov 25, 2022, 8:00 AM EST - 3 years ago

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Nov 18, 2022, 5:30 PM EST - 3 years ago

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Nov 8, 2022, 6:00 AM EST - 3 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Sep 30, 2022, 7:42 PM EDT - 3 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Sep 15, 2022, 8:07 AM EDT - 4 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Sep 15, 2022, 7:00 AM EDT - 4 years ago

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Aug 25, 2022, 8:31 PM EDT - 4 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

May 17, 2022, 8:13 AM EDT - 4 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

May 2, 2022, 8:00 AM EDT - 4 years ago

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Apr 29, 2022, 4:00 PM EDT - 4 years ago

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

Apr 25, 2022, 9:30 AM EDT - 4 years ago

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Jan 20, 2022, 8:00 AM EST - 4 years ago

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma